284 related articles for article (PubMed ID: 23944368)
41. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L.
Aragane Y; Kulms D; Metze D; Wilkes G; Pöppelmann B; Luger TA; Schwarz T
J Cell Biol; 1998 Jan; 140(1):171-82. PubMed ID: 9425165
[TBL] [Abstract][Full Text] [Related]
42. Death induced by CD95 or CD95 ligand elimination.
Hadji A; Ceppi P; Murmann AE; Brockway S; Pattanayak A; Bhinder B; Hau A; De Chant S; Parimi V; Kolesza P; Richards J; Chandel N; Djaballah H; Peter ME
Cell Rep; 2014 Apr; 7(1):208-22. PubMed ID: 24656822
[TBL] [Abstract][Full Text] [Related]
43. Does CD95 have tumor promoting activities?
Peter ME; Legembre P; Barnhart BC
Biochim Biophys Acta; 2005 May; 1755(1):25-36. PubMed ID: 15907590
[TBL] [Abstract][Full Text] [Related]
44. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
45. Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system.
Schlosser SF; Azzaroli F; Dao T; Hingorani R; Crispe IN; Boyer JL
Hepatology; 2000 Oct; 32(4 Pt 1):779-85. PubMed ID: 11003622
[TBL] [Abstract][Full Text] [Related]
46. CD95/Fas ligand induced toxicity.
Haluck-Kangas A; Peter ME
Biochem Soc Trans; 2023 Feb; 51(1):21-29. PubMed ID: 36629505
[TBL] [Abstract][Full Text] [Related]
47. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.
Bernassola F; Scheuerpflug C; Herr I; Krammer PH; Debatin KM; Melino G
Cell Death Differ; 1999 Jul; 6(7):652-60. PubMed ID: 10453076
[TBL] [Abstract][Full Text] [Related]
48. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.
Barnhart BC; Legembre P; Pietras E; Bubici C; Franzoso G; Peter ME
EMBO J; 2004 Aug; 23(15):3175-85. PubMed ID: 15272306
[TBL] [Abstract][Full Text] [Related]
49. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
50. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis.
Schmidt M; Lügering N; Lügering A; Pauels HG; Schulze-Osthoff K; Domschke W; Kucharzik T
J Immunol; 2001 Jan; 166(2):1344-51. PubMed ID: 11145719
[TBL] [Abstract][Full Text] [Related]
51. Targeting the Fas/FasL signaling pathway in cancer therapy.
Villa-Morales M; Fernández-Piqueras J
Expert Opin Ther Targets; 2012 Jan; 16(1):85-101. PubMed ID: 22239437
[TBL] [Abstract][Full Text] [Related]
52. Role of metalloproteases in the CD95 signaling pathways.
Devel L; Guedeney N; Bregant S; Chowdhury A; Jean M; Legembre P
Front Immunol; 2022; 13():1074099. PubMed ID: 36544756
[TBL] [Abstract][Full Text] [Related]
53. 3D Cellular Architecture Modulates Tyrosine Kinase Activity, Thereby Switching CD95-Mediated Apoptosis to Survival.
Gülcüler Balta GS; Monzel C; Kleber S; Beaudouin J; Balta E; Kaindl T; Chen S; Gao L; Thiemann M; Wirtz CR; Samstag Y; Tanaka M; Martin-Villalba A
Cell Rep; 2019 Nov; 29(8):2295-2306.e6. PubMed ID: 31747602
[TBL] [Abstract][Full Text] [Related]
54. Early activation of CD95 is limited and localized to the cytotoxic synapse.
Sánchez MF; Murad F; Gülcüler Balta GS; Martin-Villalba A; García-Sáez AJ; Carrer DC
FEBS J; 2018 Aug; 285(15):2813-2827. PubMed ID: 29797791
[TBL] [Abstract][Full Text] [Related]
55. The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway.
Tauzin S; Chaigne-Delalande B; Selva E; Khadra N; Daburon S; Contin-Bordes C; Blanco P; Le Seyec J; Ducret T; Counillon L; Moreau JF; Hofman P; Vacher P; Legembre P
PLoS Biol; 2011 Jun; 9(6):e1001090. PubMed ID: 21713032
[TBL] [Abstract][Full Text] [Related]
56. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
Mollinedo F; Gajate C
Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
[TBL] [Abstract][Full Text] [Related]
57. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
Chatterjee D; Schmitz I; Krueger A; Yeung K; Kirchhoff S; Krammer PH; Peter ME; Wyche JH; Pantazis P
Cancer Res; 2001 Oct; 61(19):7148-54. PubMed ID: 11585748
[TBL] [Abstract][Full Text] [Related]
58. The dual role of the CD95 and CD95L signaling pathway in glioblastoma.
Zhang Y; Jin T; Dou Z; Wei B; Zhang B; Sun C
Front Immunol; 2022; 13():1029737. PubMed ID: 36505426
[TBL] [Abstract][Full Text] [Related]
59. Lipid rafts and Fas/CD95 signaling in cancer chemotherapy.
Gajate C; Mollinedo F
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):274-83. PubMed ID: 21762074
[TBL] [Abstract][Full Text] [Related]
60. Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils.
Förster A; Falcone FH; Gibbs BF; Preussner LM; Fiebig BS; Altunok H; Seeger JM; Cerny-Reiterer S; Rabenhorst A; Papenfuss K; Valent P; Kashkar H; Hartmann K
Leuk Lymphoma; 2013 Apr; 54(4):835-42. PubMed ID: 22989017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
